Objective: To analyse 12-month response to GH treatment in a single-country cohort of hypopituitary adult patients with GH deficiency (GHD) in regards to health-related quality of life (HRQoL) and insulin-like growth factor-1 (IGF-1) compared with values from general population sample. Moreover, association between the response in HRQoL and the IGF-1 values in patients and in the background population was investigated. Design: HRQoL was assessed by quality of life assessment of GH deficiency in adults (QoL-AGHDA) in 651 patients retrieved from the German KIMS (Pfizer International Metabolic Database) before and after 12 months of GH replacement and in a sample drawn from a cross-sectional study in Germany (nZ2734). IGF-1 was measured in KIMS patients and in the population-based study with the same assay technique. Results: In KIMS patients, mean QoL-AGHDA scores before GH replacement were 9.2G6.8 (8.7G6.8) in women (men) and in the general population sample 4.5G5.3 (4.3G5.0) in women (men). Mean differences in QoL-AGHDA scores were statistically significant for all age categories (P!0.05). The mean IGF-1 SDS of KIMS patients before GH replacement was K1.1G1.4 (K0.8G1.4) in women (men). After GH replacement, a significant increase of IGF-1 concentration and a significant decrease of QoL-AGHDA scores near to age-and gender-specific population-based values were observed. Conclusions: This study confirms an improvement in HRQoL and an increase of IGF-1 SDS in GH-replaced adults, which approximated the values of general population. However, there was no association between IGF-1 values and HRQoL assessment as one of the important treatment outcomes.

No abstract

No abstract

No abstract